Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats

0462516 - FGÚ 2017 RIV GB eng J - Článek v odborném periodiku
Holubová, M. - Zemenová, J. - Mikulášková, Barbora - Panajotová, V. - Stöhr, J. - Haluzík, M. - Kuneš, Jaroslav - Železná, B. - Maletínská, L.
Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats.
Journal of Endocrinology. Roč. 229, č. 2 (2016), s. 85-96. ISSN 0022-0795. E-ISSN 1479-6805
Grant CEP: GA TA ČR(CZ) TE01020028; GA ČR(CZ) GA15-08679S
Institucionální podpora: RVO:67985823
Klíčová slova: prolactin-releasing peptide * lipidization * diet-induced obesity * ZDF rats * food intake rat
Kód oboru RIV: ED - Fyziologie
Impakt faktor: 4.706, rok: 2016

Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity, but are ineffective after peripheral application, owing to a limited ability to cross the blood–brain barrier. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both Prrp-knockout and Prrp receptor-knockout mice. The aim of this study was to characterize the subchronic effect of a palmitoylated PrRP analog in two rat models of obesity and diabetes: diet-induced obese Sprague–Dawley rats and leptin receptor-deficient Zucker diabetic (ZDF) rats. In the rats with diet-induced obesity (DIO), a two-week intraperitoneal treatment with palmitoylated PrRP lowered food intake by 24% and body weight by 8%. This treatment also improved glucose tolerance and tended to decrease leptin levels and adipose tissue masses in a dose-dependent manner. In contrast, in ZDF rats, the same treatment with palmitoylated PrRP lowered food intake but did not significantly affect body weight or glucose tolerance, probably in consequence of severe leptin resistance due to a nonfunctional leptin receptor. Our data indicate a good efficacy of lipidized PrRP in DIO rats. Thus, the strong anorexigenic, body weight-reducing, and glucose tolerance-improving effects make palmitoylated PrRP an attractive candidate for anti-obesity treatment.
Trvalý link: http://hdl.handle.net/11104/0261964